0.4128
전일 마감가:
$0.458
열려 있는:
$0.44
하루 거래량:
140.38K
Relative Volume:
0.26
시가총액:
$16.12M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
-0.1336
EPS:
-3.09
순현금흐름:
$-101.06M
1주 성능:
-4.22%
1개월 성능:
+39.93%
6개월 성능:
-20.48%
1년 성능:
-87.53%
Athira Pharma Inc Stock (ATHA) Company Profile
명칭
Athira Pharma Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ATHA
Athira Pharma Inc
|
0.4128 | 17.88M | 0 | -117.67M | -101.06M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
2024-08-19 | 개시 | Rodman & Renshaw | Buy |
2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2022-07-07 | 개시 | Mizuho | Buy |
2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
2022-05-10 | 개시 | BTIG Research | Buy |
2022-04-21 | 개시 | Berenberg | Buy |
2021-12-15 | 개시 | Goldman | Neutral |
2020-10-13 | 개시 | Goldman | Buy |
2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
2020-10-13 | 개시 | Jefferies | Buy |
2020-10-13 | 개시 | Stifel | Buy |
모두보기
Athira Pharma Inc 주식(ATHA)의 최신 뉴스
What are Athira Pharma Inc. company’s key revenue driversCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Reversal indicators forming on Athira Pharma Inc. stockShort-Term Profit Alert With Entry Forecast - Newser
Sector ETF performance correlation with Athira Pharma Inc. Smart Stock Forecast Using AI Algorithms - Newser
What is Athira Pharma Inc. company’s growth strategyInvest confidently with expert support - jammulinksnews.com
What makes Athira Pharma Inc. stock price move sharplyUnlock exclusive investment alerts - jammulinksnews.com
What are the latest earnings results for Athira Pharma Inc.Unprecedented growth rates - jammulinksnews.com
Published on: 2025-07-27 20:04:45 - jammulinksnews.com
Athira Pharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Trading Strategy Suggestions - Newser
How Athira Pharma Inc. stock performs during market volatilitySolid Return Trade Selections - Newser
Is it the right time to buy Athira Pharma Inc. stockUnstoppable trading performance - jammulinksnews.com
Buy Signal for Athira Pharma Inc. Stock Key Technical Indicators to WatchFree Stock Market Return Analysis - Newser
Why Athira Pharma Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
Is Athira Pharma Inc. a good long term investmentMarket-crushing profits - PrintWeekIndia
Athira Pharma Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional
What drives Athira Pharma Inc. stock priceHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Athira Pharma Inc. stockSkyrocketing investment returns - jammulinksnews.com
Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World
Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo
Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World
ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma Holds Annual Stockholders Meeting - TipRanks
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com
This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance
Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus
Athira Pharma Inc (ATHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):